Tech Company Financing Transactions
Ambrx Funding Round
On 7/5/2006, Ambrx secured $52 million in Series C funding from 5AM Ventures, Presidio Partners and Roche Venture Fund.
Transaction Overview
Company Name
Announced On
7/5/2006
Transaction Type
Venture Equity
Amount
$52,000,000
Round
Series C
Proceeds Purpose
Net proceeds will be used to further expand Ambrx's novel protein modification platform, support the development of its product pipeline and for general working capital purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10975 North Torrey Pines Rd.
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Ambrx is a biopharmaceutical company that develops protein therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Feng Tian
Chief Medical Officer
Joy Yan
Vice President
Sukumar Sakamuri
VP - Bus. Development
Simon Allen
VP - Bus. Development
Ying Buechler
VP - Finance
Dana Zhang
VP - R & D
Shawn Zhang
Browse more venture capital transactions:
Prev: 7/5/2006: EcoSMART Technologies venture capital transaction
Next: 7/5/2006: Kontera venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs